Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

NCT02000531 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Erlotinib
DRUG: Chemotherapy

Sponsor

Hoffmann-La Roche